Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer

British Journal of Cancer

Volumn 103, Issue 12, 2010, Pages 1794-1800

  Mukherjee, A ^a   Shehata, M ^a   Moseley, P ^a   Rakha, E ^a   Ellis, I ^a   Chan, S ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

biomarkers; breast cancer; neo adjuvant therapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TOPOISOMERASE 2 ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST FIBROSIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCALLY ADVANCED PRIMARY BREAST CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650022491     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605960     Document Type: Article

References (40)

1. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE (2006) Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. J Clin Pathol 59(7): 729-735
2. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4(3): E90
3. Bozzetti C, Musolino A, Camisa R, Bisagni G, Flora M, Bassano C, Martella E, Lagrasta C, Nizzoli R, Personeni N, Leonardi F, Cocconi G, Ardizzoni A (2006) Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline- based chemotherapy in primary breast cancer: The role of anthracycline dose intensity. Am J Clin Oncol 29(2): 171-177
4. Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA (2005) Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin- based neoadjuvant chemotherapy. Cancer 104(4): 676-681
5. Cardoso F, Piccart MJ (2003) The best use of chemotherapy in the adjuvant setting. Breast 12(6): 522-528 (Pubitemid 38008668)
6. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8): 2329-2334
7. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J, 303 Study Group (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 7(8): 2341-2354 (Pubitemid 29368232)
8. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16(3): 16223-16228
9. Colleoni M, Orvieto E, Nolé F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, Sacchini V, Veronesi P, Zurrida S, Orecchia R, Goldhirsch A (1999) Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35(4): 574-579
10. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A (2008) Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. Ann Oncol 9(3): 465-472
11. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1): 105-113
12. Desmedt C, Azambuja E, Larsimont D, Rouas G, Di Leo A, Delaloge S, Duhem C, D'Hondt V, Piccart M, Sotiriou C (2009) Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial. J Clin Oncol 27(15s): Abstr 523
13. Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D (2008) Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime?. Eur J Cancer 44(18): 2791-2798
14. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ (2001) HER-2 and topoisomeraseII alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12: 1081-1089
15. Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3: 1207-1214 (Pubitemid 39440165)
16. Esteva FJ, Hortobagyi GN (2009) Topoisomerase IIa amplification and anthracycline-based chemotherapy: The jury is still out. J Clin Oncol 27(21): 3416-3417
17. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ (2003) Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 88(3): 406-412
18. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15(1): 68-74
19. Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ (2010) Association between HER2, TOP2A, and response to anthracycline- based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 120(2): 481-489
20. MacGrogan G, Rudolph P, Mascarel Id I, Mauriac L, Durand M, Avril A, Dilhuydy JM, Robert J, Mathoulin-Pélissier S, Picot V, Floquet A, Sierankowski G, Coindre JM (2003) DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 89(4): 666-671
21. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200(5): 633-639
22. Martin-Richard M, Muñoz M, Albanell J, Colomo L, Bellet M, Rey MJ, Tabernero J, Alonso C, Cardesa A, Gascon P, Fernandez PL (2004) Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. 66(5): 388-394
23. Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane database of systematic reviews (Online) 18(2): CD005002
24. Mieog JS, van der Hage JA, van de Vijuer MJ, van de Velde CJ (2006) Tumor response to preoperative anthracycline-based chemotherapy in operable breast cancer: The predictive role of p53 expression. Eur J Cancer 42(10): 1369-1379
25. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102(38): 3550-13555
26. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez- Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16): 5367-5374
27. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine LE, Huntsman DG, Bramwell VH, Andrulis IL, Pritchard KI (2006) Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). J Clin Oncol 24(18S): 533
28. Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M (2008) Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 17(5): 506-511
29. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K (2003a) Measuring response in solid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33(10): 533-537
30. Park K, Kim J, Lim S, Han S (2003b) Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39(5): 631-641
31. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4): 495-506
32. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1): 25-32
33. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: A critical review. J Clin Oncol 26(15): 2568-2581
34. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7): 2302-2310
35. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12(5): 1533-1539
36. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16): 5678-5685
37. Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas- García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10(10): 646-653
38. Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K (2010) Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol 136: 1029-1037
39. Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, Samonigg H, Bauernhofer T (2007) The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracyclinebased neoadjuvant chemotherapy of breast cancer. Am J Clin Pathol 128(4): 630-637
40. Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2008) Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline treated patients. Breast Cancer Res Treat 111(1): 27-44